Methyl 4-[3-(3,4,5-trimethoxyphenyl)propanoyloxy]benzoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Methyl 4-[3-(3,4,5-trimethoxyphenyl)propanoyloxy]benzoate
• 化学式: C₂₀H₂₂O₇
• 分子量: 374.4
• InChiKey: LJHOSUUWZPGKPW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  27
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  80.3
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents
  申请人：The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone

  公开号：US11376242B2

  公开（公告）日：2022-07-05

  Provided are methods and compositions for identifying candidate agents for treatment of obesity, liver disease, and/or diabetes. Such methods include, e.g., contacting a mammalian cell or cell population with a test agent, and measuring an expression level and/or activity level of ClpP in the mammalian cell or in cells of the cell population. Also provided are methods and compositions for treating an individual (e.g., one who is obese and/or has diabetes). Treatment methods include administering an inhibitor of ClpP to the individual (e.g., to prevent or reduce weight gain, to increase insulin sensitivity, and/or to increase glucose tolerance).

  本文提供了用于鉴定治疗肥胖症、肝病和/或糖尿病的候选药物的方法和组合物。这些方法包括，例如，用测试剂接触哺乳动物细胞或细胞群，并测量哺乳动物细胞或细胞群中 ClpP 的表达水平和/或活性水平。还提供了治疗个体（如肥胖和/或糖尿病患者）的方法和组合物。治疗方法包括给个体施用ClpP抑制剂（例如，防止或减少体重增加、增加胰岛素敏感性和/或增加葡萄糖耐量）。
• METHODS AND COMPOSITIONS FOR TREATING OBESITY AND/OR DIABETES AND FOR IDENTIFYING CANDIDATE TREATMENT AGENTS
  申请人：The J. David Gladstone Institutes

  公开号：US20190000817A1

  公开（公告）日：2019-01-03

  Provided are methods and compositions for identifying candidate agents for treatment of obesity, liver disease, and/or diabetes. Such methods include, e.g., contacting a mammalian cell or cell population with a test agent, and measuring an expression level and/or activity level of ClpP in the mammalian cell or in cells of the cell population. Also provided are methods and compositions for treating an individual (e.g., one who is obese and/or has diabetes). Treatment methods include administering an inhibitor of ClpP to the individual (e.g., to prevent or reduce weight gain, to increase insulin sensitivity, and/or to increase glucose tolerance).